Physician profile
Josh E Amato
NPI 1467401828
$1,750.40
in general payments reported to CMS, 2019-2025
17 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $320 · 2021: $131 · 2022: $296 · 2023: $307 · 2024: $313 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $804.20 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $317.11 | 2022-2024 | Infuse, Miebo, Xiidra |
| Abbvie INC. | $224.35 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Johnson & Johnson Surgical Vision, INC. | $151.26 | 2019-2025 | Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $130.69 | 2020-2021 | |
| Glaukos Corporation | $128.71 | 2023 | |
| Mallinckrodt Hospital Products INC. | $119.32 | 2020-2021 | |
| Ivantis, INC | $117.38 | 2019 | |
| Alcon Vision LLC | $95.06 | 2022-2025 | Hydrus Microstent, Simbrinza |
| Novartis Pharmaceuticals Corporation | $94.54 | 2019-2023 | |
| Oyster Point Pharma, INC. | $81.35 | 2022-2023 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $76.00 | 2021-2022 | |
| The Cameron-Ehlen Group, INC. | $48.63 | 2020 | |
| Ocular Therapeutix, INC. | $43.94 | 2019-2023 | Dextenza |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Horizon Therapeutics Plc | $34.33 | 2021-2023 | Tepezza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $31.65 | 2025 | Izervay |
| Thea Pharma INC. | $17.28 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josh Amato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.